{
  "id": "granulocyte-colony-stimulating-factor",
  "title": "Granulocyte Colony-Stimulating Factor",
  "lang": "en",
  "source_lang": "en",
  "summary": "Granulocyte colony-stimulating factor is a cytokine that regulates neutrophil production and is used medically to support neutrophil recovery and mobilize blood-forming stem cells.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "G-CSF",
    "Colony-stimulating factor 3",
    "CSF3"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/granulocyte-colony-stimulating-factor/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/granulocyte-colony-stimulating-factor/",
      "json": "https://aiwiki.page/zh/granulocyte-colony-stimulating-factor.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Granulocyte colony-stimulating factor (G-CSF) is a cytokine that promotes the production, maturation, and survival of neutrophils, white blood cells involved in defense against infection. It is a major regulator of neutrophil development in the bone marrow and helps increase their availability during infection and inflammation. Manufactured forms of G-CSF are used to reduce the duration of certain forms of neutropenia—an abnormally low neutrophil count—and to mobilize blood-forming stem cells into the circulation for collection."
    },
    {
      "heading": "Molecular characteristics",
      "text": "Human G-CSF is encoded by the CSF3 gene on chromosome 17. It is a secreted protein with a predominantly four-helix structure. Alternative splicing produces forms with different lengths; the principal mature form contains 174 amino acids.\n\nNaturally produced human G-CSF undergoes glycosylation. Therapeutic preparations differ in how they are manufactured and whether they carry carbohydrate groups. These differences do not change their central function of activating the G-CSF receptor, although they can affect pharmaceutical properties.\n\nG-CSF is distinct from granulocyte–macrophage colony-stimulating factor (GM-CSF). Despite their similar names, they bind different receptors and have different biological effects. G-CSF acts predominantly on the neutrophil lineage, whereas GM-CSF has broader effects on several myeloid cell populations."
    },
    {
      "heading": "Production and physiological functions",
      "text": "G-CSF can be produced by several cell types, including macrophages, endothelial cells, and fibroblasts. Its production increases in response to microbial products and inflammatory signals. This connects the detection of infection in tissues with increased neutrophil output from the bone marrow.\n\nWithin hematopoiesis, G-CSF supports the proliferation and differentiation of committed neutrophil precursors. It also promotes the release of mature neutrophils into the blood and can enhance aspects of their function and survival. These effects contribute to “emergency granulopoiesis,” the accelerated production of granulocytes during increased demand.\n\nNeutrophils participate in innate immunity, including the ingestion and destruction of bacteria and fungi. G-CSF therefore supports host defense largely by regulating the number and activity of these cells, rather than by directly killing microorganisms."
    },
    {
      "heading": "Receptor and signaling",
      "text": "G-CSF acts through the G-CSF receptor, also called CSF3R or CD114. This receptor is expressed prominently on cells of the neutrophil lineage.\n\nBinding of G-CSF changes receptor organization and activates associated intracellular signaling proteins. The receptor does not possess an intrinsic protein kinase domain. Instead, it recruits signaling machinery that activates pathways including JAK–STAT, RAS–MAPK, and PI3K–AKT. These pathways influence gene expression, proliferation, differentiation, and resistance to apoptosis.\n\nSignaling is limited by regulatory mechanisms, including receptor internalization and inhibitory proteins. The response depends on the developmental stage and condition of the responding cell, so G-CSF does not produce identical effects throughout the neutrophil lineage."
    },
    {
      "heading": "Therapeutic preparations",
      "text": "Medicinal G-CSF is produced using recombinant DNA technology. Major preparations include:\n\n- Filgrastim: a nonglycosylated recombinant form produced in bacteria, with an additional amino-terminal methionine compared with the corresponding mature human protein.\n- Lenograstim: a glycosylated recombinant form produced in mammalian cells and available in some jurisdictions.\n- Pegfilgrastim: filgrastim attached to polyethylene glycol, which prolongs its persistence in the body.\n\nBiosimilar versions of several G-CSF medicines are also available. Approved indications and formulations vary between regulatory jurisdictions.\n\nLong-acting formulations reduce the frequency of administration in specified treatment settings. Pegfilgrastim clearance is substantially influenced by neutrophils, so its elimination increases as neutrophil numbers recover."
    },
    {
      "heading": "Established medical uses",
      "text": "Chemotherapy-associated neutropenia\n\nSome forms of chemotherapy suppress bone-marrow production of blood cells. G-CSF is used in selected cancer treatment settings to reduce the duration of severe neutropenia and the incidence of febrile neutropenia, a syndrome involving fever and a low neutrophil count.\n\nIts principal role in this setting is supportive: it promotes recovery of neutrophils rather than directly treating the cancer. It does not eliminate infection risk and is not an antimicrobial treatment.\n\nSevere chronic neutropenia\n\nG-CSF is used in certain congenital, cyclic, and idiopathic forms of severe chronic neutropenia. It can increase circulating neutrophil counts and reduce infection-related complications. Responses and long-term risks differ according to the underlying disorder.\n\nStem-cell mobilization and transplantation\n\nG-CSF causes hematopoietic stem and progenitor cells to move from the bone marrow into peripheral blood. This allows their collection by apheresis for hematopoietic stem-cell transplantation, using either a patient's own cells or cells from a donor.\n\nMobilization involves changes in the marrow environment and in signals that normally retain stem cells within it. It is not simply a consequence of increasing neutrophil production. G-CSF is also used in specified transplantation settings to accelerate neutrophil recovery.\n\nRadiation injury\n\nSome G-CSF products have regulatory approval for increasing survival after exposure to myelosuppressive doses of radiation. This use addresses injury to the blood-forming system; it does not reverse every form of radiation damage."
    },
    {
      "heading": "Adverse effects and limitations",
      "text": "Bone pain is a common adverse effect of therapeutic G-CSF. Other effects include injection-site reactions and increases in circulating white blood cells. Uncommon but serious adverse reactions include splenic rupture, severe allergic reactions, acute respiratory distress syndrome, capillary leak syndrome, and aortitis.\n\nG-CSF can affect cells beyond the immediate neutrophil precursor population. Because some malignant myeloid cells express its receptor, its use in myeloid diseases depends on the specific disease and treatment context.\n\nCertain congenital neutropenia syndromes carry an intrinsic risk of progression to myelodysplastic syndromes or acute myeloid leukemia. Long-term observations in these patients require careful interpretation: the underlying disease, acquired genetic changes, and treatment exposure cannot be treated as interchangeable explanations for that risk."
    },
    {
      "heading": "Historical development",
      "text": "Research on colony-stimulating factors grew from experiments in which blood-forming precursor cells produced colonies in semisolid culture. Different factors were distinguished by the cell populations whose growth they supported.\n\nCloning of the human G-CSF gene in the 1980s enabled large-scale recombinant production and clinical investigation. Filgrastim received its first United States approval in 1991. Subsequent development produced longer-acting preparations and biosimilars, expanding the pharmaceutical forms available for neutrophil support and stem-cell mobilization."
    }
  ],
  "links": [
    "cytokine",
    "neutrophil",
    "inflammation",
    "neutropenia",
    "gene",
    "protein",
    "alternative-splicing",
    "glycosylation",
    "macrophage",
    "hematopoiesis",
    "innate-immunity",
    "bacteria",
    "gene-expression",
    "apoptosis",
    "recombinant-dna",
    "chemotherapy",
    "cancer",
    "hematopoietic-stem-cell-transplantation"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}